Presenter's Information

Ron Waksman, MD

Country USA
Specialty Interventional Cardiologist
  1. Life Time Management of TAVR and REVIVE Trial
  2. Solution DEB With Sirolimus for ISR and De-Vono Lesions
  3. International BASILICA and CHIMNEY Registry Results
  4. What Can We Look Forward to from the Magnesium Scaffold?
  5. Focusing on the Clinical Importance of Conformability
  6. [Early vs. New Devices] Pro: SYMPLICITY Obviate Imprudent New Devices
  7. No Benefits, Time to Rethink?
  8. Highlights of Recent Clinical Trials from ACCi2.13: Cangrelor for PCI, Statins for CIN and PE Treatment
  9. Update on the Drug-eluting Magnesium Absorbable Scaffold: Two-year Results from the BIOSOLVE Trial
  10. Against: Dispelling Myths, No Benefits in Reality
  11. Featured Lecture: The Gold Standard for PCI Will Be Bioabsorbable DES in 5-10 Years
  12. Can IVUS Predict FFR? Lessons from VERDICT and F1RST
  13. Not a Believer: All Plaques Are Potentially Vulnerable!
  14. Role of Genotyping and Point-of-Care Testing in Clopidogrel, Parsugrel, and Ticagrelor
  15. The BIOTRONIK Bioabsorbable Magnesium Scaffold DREAMS
  16. Aortic Valvuloplasty in 2009: Indications and Results
  17. Nanoparticle or Nanomatrix Technologies for DES
  18. Treatment of DES In-Stent Restenosis
  19. Strategies for PCI of SVG Disease
  20. Structural Heart Disease Intervention: "New Opportunities to the Interventional Cardiologist with Structural Heart Disease"
  21. Future in Vulnerable Plaque Imaging
  22. Emerging Technologies
  23. Not Stenting, Conservative Medical Therapy Is the Best Choice.
  24. Perspectives on the Use of Fondaparinux in ACS: Transitioning to the Cath Lab
  25. Not So Fast: The Data Are Circumstantial
  26. The Clinical Spectrum of DES Thrombosis: Multifactorial Causes, Clinical Presentations, and Recommended Treatment Strategies
  27. How Long Patients Will Be on Dual Antiplatelet Therapy?
  28. Nuts and Bolts of Clinical Trials: DSMB, Event Committees, Core Labs, Data Standards
  29. Treatment Modalities for Diagnosing and Treatment of Vulnerable Plaque
  30. Bioabsorbable Stent Technology
  31. DES Thrombosis How Long Patients Will Be on Dual Antiplatelet Therapy?
  32. i2 Late-Breaking New Technologies Highlights
  33. Regional Photodynamic Therapy for Vulnerable Plaque Stabilization
  34. REWARDS: Non- Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents in the Real World: 1-Year Results From a Large, Single Center Registry
  35. Final Results From the ORBIT Clinical Trials
  36. Metallic Biodegradeable Stent
Conference Slides
Category